# Blood Screening Market > Blood Screening Market Research Report By Technology (Nucleic Acid Amplification Test, Enzyme-Linked Immunosorbent Assay, Next-Generation Sequencing), Product and Services (Reagents, Instruments) and End User (Hospitals and Clinics) - Forecast till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.2% - **2024:** $ 3.4 Billion - **2025:** $ 3.75 Billion - **2035:** $ 9.9 Billion - **Key Players:** Companies such as Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Becton Dickinson and Company (US), Ortho Clinical Diagnostics (US), Grifols (ES), Bio-Rad Laboratories (US), Hologic (US) are some of the major participants in the global market. **Report ID:** MRFR/MED/5434-HCR · **Pages:** 85 · **Author:** Rahul Gotadki · **Last Updated:** June 26, 2026 **URL:** https://www.marketresearchfuture.com/reports/blood-screening-market-6899 --- ## Market Summary ## **Blood Screening Market Overview** Blood Screening Market Size was valued at USD 2.70 Billion in 2023. The Global Blood Screening industry is projected to grow from USD 3.40 Billion in 2024 to USD 5.60 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.20% during the forecast period (2024 - 2032). Increasing blood donations and transfusion-related screenings, the prevalence of infectious diseases, the growing geriatric population, and awareness regarding transfusion-transmitted illnesses are the key market drivers boosting blood screening market share.  Source: Primary Research, Secondary Research, _Market Research Future_ Database, and Analyst Review The important factors driving the market share of blood screening are the rise in blood donations and the implementation of screenings linked to transfusion, the increasing frequency of infectious diseases, the expanding population of elderly individuals, and the heightened awareness around disorders transmitted by transfusion. The market's quick expansion may be attributed to many significant causes, namely the upward trend in blood donations, the rising frequency of infectious illnesses, and the proactive involvement of governmental entities. The market is being driven by the growing awareness of healthcare and the increasing acceptance of nucleic acid amplification tests (NAT). Furthermore, the market expansion has been propelled by the implementation of healthcare programs by governmental bodies, the augmentation of healthcare spending, and the improvements in blood screening technologies. Nevertheless, the expansion of the market is hindered by many issues including rigorous regulatory clearances, a scarcity of experienced workforce, and elevated operational expenses. The worldwide blood screening market is anticipated to see profitable potential with the use of pathogen reduction technologies and advancements in microbiology screening and multiplexing techniques. **In August 2023,**C2N Diagnostics, a developer of a blood test for Alzheimer's disease, has unveiled an updated iteration of their beta amyloid protein screener. With increasing public optimism over potential cures for Alzheimer's disease, the company is preparing for a widespread implementation of the test across the nation. The clinical care exam functions as a follow-up to the PrecivityAD test, which was initially introduced around three years ago. Known as PrecivityAD2, this method utilizes mass spectrometry to identify trace amounts of certain proteins that have migrated from amyloid plaques in the brain to the circulation. ## **Blood Screening Market Trends** Automated molecular platforms for blood screening are becoming a popular strategy among leading market players, fueling market growth. Blood screening tests aim to ensure the security of donated blood units and to find any signs of transmissible transfusion infections (TTIs) in the blood. The transition from manual to automated screening platforms has been critical in identifying contagious transfusion infections (TTIs) in blood samples. In the transfusion screening process, growing automation is anticipated to reduce human error. These screening tests generally impact most medical decisions in blood banks and hospitals. For instance, F. Hoffmann-La Roche Ltd. confirmed the CE-IVD launch of "cobas" in December 2019, which is intended to be utilized for blood donation screening and locates the Zika virus in human plasma. As a result, the adoption of these automated molecular platforms in blood donation facilities has increased due to the introduction of these platforms by key players. This will drive the growth of the blood screening market CAGR over the forecasted period. Other key factors boosting the development of the Blood Screening Market revenue include increasing blood donations and blood donors, raising awareness of the safety of donated blood, growing the prevalence of infectious diseases, and various government initiatives. The number of blood donations worldwide in 2022 is estimated to be around 118.5 million. Additionally, the WHO suggests that blood donations be screened for illnesses before use, including hepatitis B, syphilis, and other sexually transmitted diseases (STDs). ## **Blood Screening Market Segment Insights** ### **Blood Screening Technology Insights** Based on materials, the Blood Screening Market segmentation includes nucleic acid amplification tests, enzyme-linked immunosorbent assay, and next-generation sequencing. The nucleic acid amplification tests segment held the majority share in 2022, contributing to around ~45-47% of the Blood Screening Market revenue. The advanced benefits of nucleic acid amplification test technology, such as high specificity and sensitivity for early detection, account for most of the share. The test detects nucleic acid sooner than other screening methods, narrowing the window period for HBV, HCV, and HIV infections. In addition, its largest share is also influenced by the technology's widespread use in hospitals, clinical labs, and blood banks. Moreover, the widespread adoption of this technology in developing and emerging markets creates new avenues for the segment's expansion. **Figure 1: Global Blood Screening Market, by Technology, 2022 & 2032 (USD Billion)** Source: Primary Research, Secondary Research, _Market Research Future_ Database, and Analyst Review ### **Blood Screening Product & Services Insights** Applications have bifurcated the Blood Screening Market data into reagents and instruments. The reagents segment dominated the market in 2022 and is anticipated to be the faster-growing segment in the forecast period 2024-2032. Reagents, a recurring expense, are widely used in immunoassays and molecular tests. Factors such as increased blood donations and transfusion-related screenings, as well as the increasing prevalence of infectious diseases, are driving the growth of this segment. Additionally, the COVID-19 outbreak has increased serological testing, which has helped grow this market segment. These kits have uses in clinical chemistry, polymerase chain reaction (PCR), diabetes, in vitro and molecular diagnostics, test strips, and the detection of illicit drugs. Reagents and kits are also used privately or at the Point of Care (POC) for DNA lineage analysis, glucose strips, and at-home pregnancy tests. ### **Blood Screening End User Insights** Based on End Users, the global Blood Screening Market segmentation has been divided into hospitals, clinics, and others. Hospitals held the most prominent segment share in 2022 due to the increasing frequency of blood transfusion procedures in these settings. Many hospitals worldwide use patient blood management programs to help with transfusion, and screening practices, primarily to improve patient outcomes, cut costs and conserve blood units. Moreover, growing collaborations between blood centers and hospitals fuel the adoption of blood screening tests in these settings, driving the blood screening market growth throughout the forecast period. **In December 2022**, PredOmix introduced a novel blood test called OncoVeryx-F, which has a unique capability to accurately detect early-stage malignancies in women with a remarkable accuracy rate of 98%. Utilizing cutting-edge metabolomics technology in conjunction with artificial intelligence (AI), this novel advancement will facilitate the detection of early-stage malignancies through screening processes. The screening method, specifically tailored for the female population, effectively and precisely detects cancer at an early stage, prior to the initiation of tumor formation. The patented technology known as OncoVeryx-F integrates metabolomics and artificial intelligence methodologies for the purpose of early cancer detection. **July 2023:** Quest Diagnostics has recently introduced the inaugural direct-to-consumer blood test designed to identify atypical levels of beta amyloid, a crucial protein associated with Alzheimer's disease that may manifest years prior to the onset of dementia symptoms. The news is a result of the recent regulatory clearance in the United States of Leqembi, a pharmaceutical product developed by Eisai in collaboration with Biogen. Leqembi is designed to eliminate amyloid from the brain and has demonstrated efficacy in slowing the progression of Alzheimer's disease in individuals in the early stages of the condition. ### **Blood Screening Regional Insights** By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Blood Screening market accounted for USD 1.14 billion in 2022 and is likely to exhibit a significant CAGR growth over the study period. The region's largest share is mainly attributed to rising blood transfusion-related screenings, increasing infectious disease prevalence, an aging population, the need for early disease detection and monitoring, rising healthcare expenditure, and the growing adoption of technologically advanced blood screening technologies. This region's dominance is further attributed to increased blood donors, widespread implementation of blood screening procedures, and improved patient affordability. Further, the major countries studied in the global market report are the U.S., Germany, Canada, France, the UK, Spain, Italy, Japan, India, Australia, China, South Korea, and Brazil. **Figure 3: BLOOD SCREENING MARKET SHARE BY REGION 2022 (%)** Source: Primary Research, Secondary Research, _Market Research Future_ Database, and Analyst Review The second-largest market share belongs to the European blood screening market, where respiratory illnesses and cancer are becoming more common. Rising government support and increased private-sector investment in the research and development of various blood screening tests are driving revenue growth in this region. For instance, F. Hoffmann-La Roche Ltd. introduced the Cobas Zika test for Cobas 6800/8800 Systems on December 16, 2019. The Cobas Zika test is designed to screen blood donations in Europe for Zika virus infection by finding RNA in human plasma samples. In addition, the European Union has made blood screening for HCV, HBV, HIV, parvovirus-19, and other viruses mandatory. Further, the German blood screening market held the largest market share, and the UK blood screening market was the fastest-growing market in the European region. The Asia-Pacific Blood Screening Market is projected to grow at the fastest CAGR from 2024 to 2032, owing to rising patient affordability and key industry players' increased focus on emerging markets. Japan, India, China, Singapore, and Australia contribute significantly to the market in the Asia Pacific region. Moreover, China’s blood screening market held the largest market share, and the Indian blood screening market was the fastest-growing market in the Asia-Pacific region. India's blood screening market differs from other Asia Pacific nations like China and Japan as of laxer regulatory requirements and the importation of the necessary equipment and materials. Expanded investments by private and international entities, which may help offer practical tests at lower prices, are expected to lead to significant growth in the Indian blood screening industry. India's well-connected network of clinical laboratories and healthcare facilities is accelerating the adoption of blood screening methods. ## **Blood Screening Key Market Players & Competitive Insights** The competitive landscape is semi-consolidated, with several domestic and international blood screening industry players operating globally. Major market players are investing heavily in research and development to develop more innovative and advanced techniques that minimize turnaround time and improve the effectiveness and accuracy of crossmatch screening. Key players use various market development strategies, including investing in adapting cutting-edge techniques, launching new technologies, mergers & acquisitions, and regional expansion to capture the largest share of global revenue. Blood screening industry competitors must provide cost-effective products and services to develop and sustain in an intensely challenging and rising global market environment. The blood screening market major players, such as BioMerieux, Siemens Healthineers, Thermo Fisher Scientific Inc, and others, are working to increase industry demand by investing in research and development activities to ensure constant innovation. The global blood screening industry has recently provided some of the most substantial advantages to reagents and instruments. Roche Diagnostics (Switzerland) is a company that provides diagnostic system solutions for hospitals, clinics, laboratories, and doctors' offices. The company creates, manufactures, and supports in-vitro diagnostic and bioanalytical instruments and software systems. It also provides test systems, molecular diagnostic reagents, blood screening products, diagnostic analysis systems, and workflow solutions. Blood glucose meters and point-of-care testing equipment are among its primary offerings. The company offers services and products to commercial diagnostic laboratories, hospitals, researchers, healthcare professionals, and pharmacists. Roche Diagnostics (Switzerland) purchased TIB Molbiol Group (Germany) in September 2021. This acquisition will broaden Roche's portfolio of molecular diagnostics solutions, including assays for infectious diseases, such as identifying SARS-CoV-2 variants. Also, Becton, Dickinson, and Company, or BD, is a multinational clinical technology company based in the United States that produces and distributes medical devices, indicator systems, and reagents. Additionally, in certain regions, BD offers consulting and analytics services. In March 2020, B.D. announced the launch of a singular blood screening test that can identify antibodies in blood to confirm current or previous COVID-19 exposure in less than 15 minutes. ### **Key Companies in the blood screening market include** ## **Blood Screening Industry Developments** **June 2021: **Grail, an American pharmaceutical and biotechnology company, has announced the release of the Galleri blood screening test, an advanced multi-cancer screening diagnostic that can detect the presence of multiple cancers. This test will assist the company in screening approximately 50 million people after its launch to obtain full FDA approval by 2023. **May 2021:** Tzar Labs, a molecular diagnostics company, and Epigeneres Biotechnology have announced the development of cancer tests for early detection. This test, which will be available by the end of 2023, will assist in determining the various stages of the disease. The company's accuracy rates for cancer screening tests are very high, and it has demonstrated results for all forms of cancer. **October 2020: **Siemens Healthineers has announced the availability of its laboratory-based total immunoglobulin test1 for identifying SARS-CoV-2 IgM and IgG immunoglobulin in the blood throughout the world. The ability to identify patients who have an adaptive immune response is made possible by the complete antibody test. ## **Blood Screening Market Segmentation** ### **Blood Screening Technology Outlook** ### **Blood Screening Product & Services Outlook** ### **Blood Screening End User Outlook** ### **Blood Screening Regional Outlook** **North America** **Europe** **Asia-Pacific** **Rest of the World** ## Market Drivers ### Regulatory Framework Enhancements The Blood Screening Market is significantly influenced by the evolving regulatory landscape. Governments and health authorities are increasingly implementing stringent regulations to ensure the safety and efficacy of blood screening processes. These regulations often mandate comprehensive testing protocols for blood products, thereby driving the demand for advanced screening technologies.   For instance, the introduction of new guidelines for blood safety has led to an uptick in the adoption of automated screening systems. This regulatory push is expected to propel the Blood Screening Market forward, as compliance with these standards necessitates investment in innovative screening solutions. ### Expansion of Healthcare Infrastructure The expansion of healthcare infrastructure, particularly in developing regions, serves as a vital driver for the Blood Screening Market. As countries invest in improving their healthcare systems, the establishment of new hospitals and diagnostic centers increases the demand for blood screening services. This growth is particularly evident in regions where access to healthcare has historically been limited.   The World Health Organization has reported a significant increase in healthcare spending in these areas, which is likely to enhance the availability of blood screening technologies. Consequently, the Blood Screening Market is expected to benefit from this infrastructural development, as more facilities seek to implement comprehensive blood screening programs. ### Increasing Prevalence of Infectious Diseases The rising incidence of infectious diseases is a crucial driver for the Blood Screening Market. As the world witnesses a surge in conditions such as hepatitis, HIV, and other blood-borne pathogens, the demand for effective blood screening solutions intensifies. According to recent estimates, the prevalence of hepatitis C alone affects millions, necessitating robust screening measures.   This trend compels healthcare providers to adopt advanced blood screening technologies to ensure patient safety and effective disease management. Consequently, the Blood Screening Market is likely to experience substantial growth as healthcare systems prioritize the implementation of comprehensive screening protocols to combat these infectious threats. ### Technological Innovations in Blood Screening Technological advancements play a pivotal role in shaping the Blood Screening Market. Innovations such as nucleic acid testing (NAT) and next-generation sequencing (NGS) have revolutionized the accuracy and efficiency of blood screening processes. These technologies enable the detection of pathogens at lower levels, enhancing the safety of blood transfusions.   The market for blood screening technologies is projected to grow significantly, with estimates suggesting a compound annual growth rate (CAGR) of over 8% in the coming years. As healthcare providers increasingly adopt these cutting-edge solutions, the Blood Screening Market is poised for transformative growth, driven by the need for precision and reliability in screening practices. ### Rising Awareness of Blood Donation and Screening The growing awareness surrounding the importance of blood donation and screening is a significant driver for the Blood Screening Market. Educational campaigns and initiatives by health organizations have led to increased public participation in blood donation drives. This heightened awareness not only encourages more individuals to donate blood but also emphasizes the necessity of thorough screening to ensure the safety of the blood supply.   As a result, the demand for blood screening services is expected to rise, with projections indicating a potential increase in screening volumes by 15% over the next few years. This trend underscores the critical role of public health education in bolstering the Blood Screening Market. ## Future Outlook The Blood Screening Market size is projected to reach USD 9.898 Billion by 2035, growing at a CAGR of 10% **New opportunities:** - Development of AI-driven diagnostic tools for enhanced accuracy. Expansion of mobile blood screening units in underserved regions. Partnerships with telehealth platforms for remote screening services. By 2035, the Blood Screening Market is expected to be robust, driven by innovation and strategic partnerships. ## Segment Insights ### By Technology: Nucleic Acid Amplification Test (Largest) vs. Next-Generation Sequencing (Fastest-Growing) The Blood Screening Market showcases diverse technologies, primarily dominated by Nucleic Acid Amplification Tests (NAAT), which account for a significant portion of the market share. NAAT's effectiveness in detecting pathogens with high sensitivity has made it a preferred choice among healthcare providers. Enzyme-Linked Immunosorbent Assay (ELISA), while important, has a smaller share in comparison, reflecting its specific application niches within [blood testing](https://www.marketresearchfuture.com/reports/blood-testing-market-5797). Meanwhile, Next-Generation Sequencing (NGS) is rapidly gaining traction, attracting considerable attention for its comprehensive and detailed analysis capabilities. The growth trends in this segment indicate a robust upward trajectory, fueled by technological advancements and increasing awareness of infectious diseases. NGS is regarded as the fastest-growing method due to its ability to handle [multiplex assays](https://www.marketresearchfuture.com/reports/multiplex-assays-market-6135) and provide rapid, accurate results. The rising incidence of viruses and a growing emphasis on precision medicine are primary drivers propelling these technologies' acceptance and market expansion in blood screening applications. Technology: Nucleic Acid Amplification Test (Dominant) vs. Next-Generation Sequencing (Emerging) Nucleic Acid Amplification Tests (NAAT) represent the dominant technology in the market share due to their unmatched sensitivity and specificity in detecting nucleic acids from pathogens. Their widespread adoption in clinical settings underscores their reliability and efficiency, making them essential for various infectious disease diagnostics. In contrast, [Next-Generation Sequencing (NGS)](https://www.marketresearchfuture.com/reports/next-generation-sequencing-market-6354) is emerging as a key player in the market, capitalizing on its ability to provide detailed genomic insights. With its growing capacity to perform large-scale genomic analyses at reduced costs and improved turnaround times, NGS is positioned to revolutionize the landscape of blood screening, particularly in identifying complex and rare infections, thereby complementing the established NAAT technology. ### By Product & Services: Reagents (Largest) vs. Instruments (Fastest-Growing) In the Blood Screening Market, 'Reagents' hold the largest share, dominating the landscape with their essential role in various testing procedures. They are critical for the accuracy and reliability of blood screening results, which underscores their importance in clinical settings. In contrast, 'Instruments' are emerging as a significant player, experiencing rapid growth as advancements in technology drive innovation in blood screening solutions. This segment is becoming increasingly vital in enhancing efficiency and accuracy in diagnostic laboratories. The growth trends in the Blood Screening Market are being significantly influenced by the rising prevalence of blood-borne diseases and an increase in awareness regarding early diagnosis. Additionally, technological advancements in instruments, including automation and digitalization, are propelling the expansion of this segment. As healthcare institutions seek to upgrade their capabilities, the demand for innovative blood screening instruments is expected to surge, further solidifying their position in the market for the foreseeable future. Reagents (Dominant) vs. Instruments (Emerging) Reagents play a dominant role in the market share due to their essential function in the testing process. They facilitate the detection of various pathogens and markers in blood samples, making them indispensable for accurate diagnostics. The continued reliance on reliable reagents amidst growing health concerns further reinforces their market position. On the other hand, instruments are emerging as a critical component of blood screening solutions. The increasing integration of advanced technologies, such as automated testing systems and point-of-care devices, is enhancing the operational capabilities of diagnostic facilities. This influx of innovative instruments is not only improving turnaround times but also elevating the accuracy of results, thereby positioning them as a rapidly growing segment in the industry. ### By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing) In the Blood Screening Market, the distribution of end users reveals that hospitals hold the largest share, driven by their comprehensive healthcare services and advanced diagnostic capabilities. Clinics, by contrast, are rapidly emerging, adopting blood screening technologies for faster diagnosis and treatment, reflecting a growing healthcare trend that prioritizes patient-centric services. The 'Others' category, which includes laboratories and research facilities, plays a supportive role but lacks the prominence of the primary segments. End Users: Hospitals (Dominant) vs. Clinics (Emerging) Hospitals dominate the market share as they are equipped with sophisticated diagnostic tools and are often the primary settings for extensive blood testing. Their established infrastructure facilitates the integration of advanced screening techniques. Conversely, clinics are emerging as significant players, driven by increased patient footfall and the need for quicker, more accessible testing solutions. These smaller, more agile facilities are adapting rapidly to technological advancements, making them appealing alternatives for routine screenings. The increase in preventive healthcare initiatives further strengthens the position of clinics in this dynamic market. ## Regional Market Share Analysis ### North America : Market Leader in Innovation North America leads in the Blood Screening Market Size, accounting for over 45% of the global revenue in 2024. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of blood-borne diseases, and stringent regulatory frameworks. The demand for rapid and accurate diagnostic tests is also on the rise, fueled by technological advancements and a growing focus on preventive healthcare.  The United States is the leading country in this market, followed by Canada. Major players like Abbott Laboratories, Thermo Fisher Scientific, and Becton Dickinson are headquartered here, contributing to a competitive landscape. The presence of these key players ensures continuous innovation and development of new screening technologies, enhancing market growth and improving patient outcomes. ### Europe : Regulatory Frameworks Drive Growth Europe Blood Screening Market was valued at USD 1.02 Billion in 2024, making it the second-largest regional market with a 30% share. The region benefits from robust healthcare systems and increasing investments in diagnostic technologies. Regulatory bodies are actively promoting blood safety and screening standards, which further drives market growth. The rising incidence of infectious diseases and the need for early diagnosis are also significant demand drivers in this region. Germany and the UK are the leading countries in the European blood screening market, with a strong presence of key players like Roche Diagnostics and Siemens Healthineers. The competitive landscape is characterized by collaborations and partnerships among companies to enhance product offerings. The focus on research and development is also prominent, ensuring that Europe remains at the forefront of blood screening innovations. ### Asia-Pacific : Rapid Growth and Expansion Asia-Pacific is witnessing rapid growth in the blood screening market, holding approximately 20% of the global share. The region's expansion is driven by increasing healthcare expenditure, rising awareness of blood-related diseases, and a growing population. Governments are investing in healthcare infrastructure and promoting initiatives for early disease detection, which are significant catalysts for market growth. China and India are the leading countries in this region, with a burgeoning demand for advanced diagnostic solutions. The competitive landscape is evolving, with both local and international players like Grifols and Bio-Rad Laboratories expanding their presence. The focus on affordable and accessible healthcare solutions is shaping the market dynamics, making Asia-Pacific a key player in the global blood screening landscape. ### Middle East and Africa : Untapped Potential in Healthcare The Middle East and Africa region is gradually emerging in the blood screening market, holding about 5% of the global share. The growth is primarily driven by increasing investments in healthcare infrastructure and rising awareness of blood safety. Governments are implementing policies to enhance healthcare access, which is expected to boost demand for blood screening technologies in the coming years. Countries like South Africa and the UAE are leading the market, with a growing number of healthcare facilities adopting advanced diagnostic solutions. The competitive landscape is characterized by a mix of local and international players, focusing on tailored solutions to meet regional needs. The presence of key players is gradually increasing, paving the way for future growth in this untapped market. ## Competitive Benchmarking The Blood Screening Market is currently characterized by a dynamic competitive landscape, driven by technological advancements, increasing prevalence of blood-related diseases, and a growing emphasis on early diagnosis. Major players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are strategically positioned to leverage innovation and expand their market presence. Abbott Laboratories (US) focuses on enhancing its diagnostic capabilities through continuous product development, while Roche Diagnostics (CH) emphasizes partnerships to bolster its research and development efforts.   Siemens Healthineers (DE) is investing in digital transformation initiatives, which collectively shape a competitive environment that prioritizes technological superiority and strategic collaborations. Key business tactics within the Blood Screening Market include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with several key players exerting substantial influence. This structure allows for a competitive interplay where innovation and strategic partnerships are pivotal in maintaining market share and driving growth.   In August 2025, Abbott Laboratories (US) announced the launch of a new blood screening platform designed to improve the accuracy and speed of infectious disease detection. This strategic move is likely to enhance Abbott's competitive edge by addressing the increasing demand for [rapid diagnostics](https://www.marketresearchfuture.com/reports/rapid-diagnostics-market-11687), thereby positioning the company favorably in a market that values efficiency and reliability. In September 2025, Roche Diagnostics (CH) entered into a collaboration with a leading biotechnology firm to develop next-generation blood screening assays.   This partnership is indicative of Roche's commitment to innovation and suggests a strategic focus on expanding its product portfolio to meet evolving market needs. Such collaborations may enhance Roche's capabilities in delivering cutting-edge diagnostic solutions, further solidifying its market position. In July 2025, Siemens Healthineers (DE) unveiled a new AI-driven analytics tool aimed at optimizing blood screening processes.   This initiative reflects Siemens' strategic emphasis on integrating artificial intelligence into its offerings, potentially revolutionizing how blood screening is conducted. The introduction of AI technologies may not only improve operational efficiencies but also enhance diagnostic accuracy, thereby attracting a broader customer base. As of October 2025, the Blood Screening Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence.   Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of adaptability and forward-thinking strategies in navigating the complexities of the market. ## Recent News & Developments **June 2021: **Grail, an American pharmaceutical and biotechnology company, has announced the release of the Galleri blood screening test, an advanced multi-cancer screening diagnostic that can detect the presence of multiple cancers. This test will assist the company in screening approximately 50 million people after its launch to obtain full FDA approval by 2023. **May 2021:** Tzar Labs, a [molecular diagnostics](https://www.marketresearchfuture.com/reports/molecular-diagnostics-market-1171) company, and Epigeneres Biotechnology have announced the development of cancer tests for early detection. This test, which will be available by the end of 2023, will assist in determining the various stages of the disease. The company's accuracy rates for cancer screening tests are very high, and it has demonstrated results for all forms of cancer. **October 2020: **Siemens Healthineers has announced the availability of its laboratory-based total immunoglobulin test1 for identifying SARS-CoV-2 IgM and IgG immunoglobulin in the blood throughout the world. The ability to identify patients who have an adaptive immune response is made possible by the complete antibody test. ## Report Scope | MARKET SIZE 2024 | 3.4(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 3.747(USD Billion) | | MARKET SIZE 2035 | 9.898(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.2% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Becton Dickinson and Company (US), Ortho Clinical Diagnostics (US), Grifols (ES), Bio-Rad Laboratories (US), Hologic (US) | | Segments Covered | Technology | | Key Market Opportunities | Integration of advanced technologies enhances accuracy and efficiency in the Blood Screening Market. | | Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the blood screening market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the projected market valuation of the Blood Screening Market by 2035?** A: The Blood Screening Market is projected to reach approximately 9.898 USD Billion by 2035. **Q: What was the market valuation of the Blood Screening Market in 2024?** A: In 2024, the Blood Screening Market was valued at 3.4 USD Billion. **Q: What is the expected CAGR for the Blood Screening Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Blood Screening Market during the forecast period 2025 - 2035 is 10.2%. **Q: Which technology segment is anticipated to show significant growth in the Blood Screening Market?** A: The Nucleic Acid Amplification Test segment is expected to grow from 1.2 USD Billion in 2024 to 3.5 USD Billion by 2035. **Q: What are the key products and services driving the Blood Screening Market?** A: Reagents and instruments are key products, with reagents projected to grow from 1.5 USD Billion in 2024 to 4.5 USD Billion by 2035. **Q: Which end-user segment is likely to dominate the Blood Screening Market?** A: Hospitals are likely to dominate the end-user segment, growing from 1.7 USD Billion in 2024 to 4.8 USD Billion by 2035. **Q: Who are the leading companies in the Blood Screening Market?** A: Key players in the Blood Screening Market include Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers. **Q: What is the growth outlook for the Enzyme-Linked Immunosorbent Assay segment?** A: The Enzyme-Linked Immunosorbent Assay segment is projected to increase from 1.0 USD Billion in 2024 to 2.8 USD Billion by 2035. **Q: How does the Next-Generation Sequencing segment perform in the Blood Screening Market?** A: The Next-Generation Sequencing segment is expected to grow from 1.2 USD Billion in 2024 to 3.6 USD Billion by 2035. **Q: What is the anticipated growth for the Clinics end-user segment in the Blood Screening Market?** A: The Clinics end-user segment is projected to grow from 1.0 USD Billion in 2024 to 2.8 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/blood-screening-market-6899*